Abstract
Graphene quantum dots (GQDs) have a wide range of applications in biomedical applications, particularly anticancer drug delivery. In this study, graphene oxide quantum dots conjugated with glucosamine and boric acid (GOQDs-GlcN-BA) with and without anticancer drug were investigated for cancer therapy. FTIR, XRD, and SEM analyses were used to characterize graphene oxide (GO), and FTIR, ICP, and TEM were used to characterize GO quantum dots. The presence of various functional groups in the FTIR analysis demonstrated the successful synthesis of GO (hydroxyl, epoxy, carboxyl, etc). Furthermore, the FTIR analysis revealed that glucosamine was successfully conjugated. The nanocomposite contained 4 w/w boron according to the ICP analysis. Furthermore, the size of all the nanocomposites synthesized ranged between 15 and 51 nm. DOX loading efficiencies of GOQDs-GlcN-DOX and GOQDs-GlcN-BA-DOX were 57% and 90%, respectively. Only 8% of DOX release occurred from GOQDs-GlcN-DOX in acidic environment and 5% of drug released at neutral pH, whereas BA addition in the nanocomposite increased DOX release up to 20% at 5.5 pH and 10% at 7.4 pH in 96 h. GOQD-GlcN-BA-DOX exhibited more cytotoxicity against MCF-7 cells compared to GOQD-GlcN-DOX. Cellular internalization of GOQD-GlcN-BA-DOX in MCF-7 was higher than observed for GOQDs-GlcN-DOX owing to sialic acid on cell surface and BA interaction. This work shows the addition of BA enhanced the loading and release of anticancer drug to GOQDs-GlcN, with higher cellular internalization, thus superior potential for anticancer drug delivery.